Stock A001360 SAMSUNG PHARM. CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News SAMSUNG PHARM. Co., LTD.

Equities

A001360

KR7001360007

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
1,718 KRW +1.72% Intraday chart for SAMSUNG PHARM. Co., LTD. +5.08% -21.01%
2023 NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd. CI
2023 NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 9 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.
CI
NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 9 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.
CI
Gemvaxzio Co., Ltd. announced that it has received KRW 7.3 billion in funding from SAMSUNG PHARM. Co., LTD.
CI
SAMSUNG PHARM. Co., LTD. Present Pancreatic Cancer Immunotherapeutic Drug, RIAVAX™, Phase III results at ASCO 2021
CI
An unknown buyer agreed to acquire 38.7% stake in Korea Stem Cell Bank Co., Ltd. from SAMSUNG PHARM. Co., LTD. for KRW 9.9 billion.
CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 9.999996279 billion in funding
CI
SAMSUNG PHARM. Co., LTD. announced that it expects to receive KRW 9.999996279 billion in funding
CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 21.7 billion in funding from Kiwoom Investment Co., Ltd., Sangsangin Plus Savings Bank Co.,Ltd.
CI
SAMSUNG PHARM. Co., LTD. completed the acquisition of an unknown minority stake in True Life Insurance Bank for KRW 12.5 billion.
CI
SAMSUNG PHARM. Co., LTD. acquired 3.1% stake in Enerzent Co., Ltd. for KRW 3 billion.
CI
SAMSUNG PHARM. Co., LTD. acquired 0.16% stake in GemVax Technology Co., Ltd. from Samsung Medicos Co., Ltd. for approximately KRW 220 million.
CI
Korea Stem Cell Bank Co., Ltd. agreed to acquire Samsung Medicos Co., Ltd. from SAMSUNG PHARM. Co., LTD. for KRW 16.3 billion.
CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 1.5 billion in funding from J & J Investment Co Ltd and other investor
CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 10.2 billion in funding from a group of investors
CI
Samsung Pharmaceutical Co., Ltd. announced that it has received KRW 5.65 billion in funding
CI
Samsung Pharmaceutical Corporation(KOSE:A001360) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index
CI
Samsung Pharmaceutical Co., Ltd. announced that it has received KRW 14.5 billion in funding from a group of investors.
CI
Samsung Pharmaceutical Co., Ltd. announced that it expects to receive KRW 14.5 billion in funding from a group of investors.
CI
Samsung Pharmaceutical Co., Ltd. completed the sale of 17.13% stake in Medizen Humancare Co.,Ltd.
CI
Samsung Pharmaceutical Corporation(KOSE:A001360) added to S&P Global BMI Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A001360 Stock
  4. News SAMSUNG PHARM. Co., LTD.